COVID-19 inactivated vaccine + quadrivalent influenza vaccine + 23-valent pneumococcal polysaccharide vaccine

This drug entry refers to the co-administration of three distinct vaccines: an inactivated COVID-19 vaccine, a quadrivalent influenza vaccine (QIV), and a 23-valent pneumococcal polysaccharide vaccine (PPSV23). This regimen is being studied by the Chinese Center for Disease Control and Prevention (China CDC) to evaluate the safety and immunogenicity of simultaneous immunization in adults aged 18 and older, particularly as a booster strategy. The inactivated COVID-19 vaccine uses killed SARS-CoV-2 virus to elicit an immune response, the QIV targets two influenza A subtypes and two influenza B lineages, and the PPSV23 provides protection against 23 common serotypes of *Streptococcus pneumoniae*. The primary goal of such co-immunization studies is to simplify vaccination schedules and improve coverage rates for respiratory pathogens.

Other names

Co-immunization of COVID-19, Influenza, and Pneumococcal Vaccines